Nucleic acids and proteins from Streptococcus groups A and B
US-9840538-B2 · Dec 12, 2017 · US
Nucleic acids and proteins from streptococcus groups A and B
US10428121B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10428121-B2 |
| Application number | US-201715805453-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 7, 2017 |
| Priority date | Oct 27, 2000 |
| Publication date | Oct 1, 2019 |
| Grant date | Oct 1, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
First claim
Opening claim text (preview).
The invention claimed is: 1. A fusion polypeptide consisting of (i) a polypeptide which has at least 95% sequence identity to SEQ ID NO: 4212 and (ii) a heterologous sequence. 2. The fusion polypeptide of claim 1 , wherein the polypeptide of (i) consists a sequence which has at least 99% sequence identity to SEQ ID NO: 4212. 3. The fusion polypeptide of claim 1 , wherein the polypeptide of (i) consists of the sequence of SEQ ID NO: 4212. 4. The fusion polypeptide of claim 1 , wherein the heterologous sequence of the fusion polypeptide comprises a histidine tag, a glutathione S-transferase (GST) tag, a signal sequence, or a leader sequence. 5. A composition comprising (a) a fusion polypeptide of claim 1 , and (b) a pharmaceutically acceptable vehicle.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10428121B2 cover?
- The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
- Who is the assignee on this patent?
- Novartis Ag, J Craig Venter Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/315. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).